348 related articles for article (PubMed ID: 24524766)
1. Personalized peptide vaccine for treatment of advanced cancer.
Sasada T; Yamada A; Noguchi M; Itoh K
Curr Med Chem; 2014; 21(21):2332-45. PubMed ID: 24524766
[TBL] [Abstract][Full Text] [Related]
2. Prospect and progress of personalized peptide vaccinations for advanced cancers.
Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
[TBL] [Abstract][Full Text] [Related]
3. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.
Noguchi M; Sasada T; Itoh K
Cancer Immunol Immunother; 2013 May; 62(5):919-29. PubMed ID: 23197273
[TBL] [Abstract][Full Text] [Related]
4. Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer.
Sasada T; Noguchi M; Yamada A; Itoh K
Hum Vaccin Immunother; 2012 Sep; 8(9):1309-13. PubMed ID: 22894962
[TBL] [Abstract][Full Text] [Related]
5. [Personalized peptide vaccine for cancer treatment; now and its future].
Waki K; Yamada A
Nihon Rinsho; 2017 Feb; 75(2):251-256. PubMed ID: 30562860
[TBL] [Abstract][Full Text] [Related]
6. [Peptide vaccination for castration-resistant prostate cancer].
Koga N; Noguchi M
Nihon Rinsho; 2014 Dec; 72(12):2147-51. PubMed ID: 25518349
[TBL] [Abstract][Full Text] [Related]
7. Current status of immunotherapy for the treatment of biliary tract cancer.
Takahashi R; Yoshitomi M; Yutani S; Shirahama T; Noguchi M; Yamada A; Itoh K; Sasada T
Hum Vaccin Immunother; 2013 May; 9(5):1069-72. PubMed ID: 23376808
[TBL] [Abstract][Full Text] [Related]
8. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
[TBL] [Abstract][Full Text] [Related]
9. [Personalized peptide vaccination].
Itoh K; Takahashi R; Yoshitomi M; Terasaki M; Noguchi M
Nihon Rinsho; 2012 Dec; 70(12):2118-23. PubMed ID: 23259383
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.
Shirahama T; Muroya D; Matsueda S; Yamada A; Shichijo S; Naito M; Yamashita T; Sakamoto S; Okuda K; Itoh K; Sasada T; Yutani S
Cancer Sci; 2017 May; 108(5):838-845. PubMed ID: 28188670
[TBL] [Abstract][Full Text] [Related]
11. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
12. Prospects for a personalized peptide vaccine against lung cancer.
Nakahara Y; Kouro T; Igarashi Y; Kawahara M; Sasada T
Expert Rev Vaccines; 2019 Jul; 18(7):703-709. PubMed ID: 31225971
[No Abstract] [Full Text] [Related]
13. Therapeutic cancer vaccines: From initial findings to prospects.
Song Q; Zhang CD; Wu XH
Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
Narita Y; Arakawa Y; Yamasaki F; Nishikawa R; Aoki T; Kanamori M; Nagane M; Kumabe T; Hirose Y; Ichikawa T; Kobayashi H; Fujimaki T; Goto H; Takeshima H; Ueba T; Abe H; Tamiya T; Sonoda Y; Natsume A; Kakuma T; Sugita Y; Komatsu N; Yamada A; Sasada T; Matsueda S; Shichijo S; Itoh K; Terasaki M
Neuro Oncol; 2019 Feb; 21(3):348-359. PubMed ID: 30500939
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
[TBL] [Abstract][Full Text] [Related]
16. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
Sakamoto S; Yutani S; Shichijo S; Morita M; Yamada A; Itoh K; Noguchi M
Cancer Immunol Immunother; 2016 Oct; 65(10):1223-31. PubMed ID: 27549314
[TBL] [Abstract][Full Text] [Related]
17. Are peptide vaccines viable in combination with other cancer immunotherapies?
Ohtake J; Sasada T
Future Oncol; 2017 Aug; 13(18):1577-1580. PubMed ID: 28776424
[No Abstract] [Full Text] [Related]
18. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K
J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665
[TBL] [Abstract][Full Text] [Related]
20. Personalized cancer vaccines: adjuvants are important, too.
Gouttefangeas C; Rammensee HG
Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]